Medication-Use Evaluation of Recombinant Human Factor VIIa
نویسندگان
چکیده
منابع مشابه
Use of Recombinant factor VIIa in Obstetrics
6 The objective of this review article was to evaluate the current literature on the increasing off-label use of rFVIIa in the management of critical obstetric hemorrhage. Given the lack of high-level evidence, there is a need to review the clinical indications, observed response and adverse events. This review is designed to aid practitioners in deciding when and how to administer rFVIIa; It m...
متن کاملThe Use of Recombinant Factor VIIa*
As described in detail in other chapters of this volume, conditions with excessive bleeding, as are seen with uterine rupture, placenta accreta, abruption and uterine atony, often require intensive resuscitation with blood components and coagulation factors. In such circumstances, blood transfusion may be life-saving, but on occasion involves exposing the patient to additional risks. Over the y...
متن کاملUse of recombinant factor VIIa for emergency reversal of anticoagulation.
CONTEXT There is limited data regarding the use of activated recombinant factor VII (rFVIIa) in anticoagulated patients requiring reversal. AIMS To identify and describe characteristics of subjects who received rFVIIa as part of emergency treatment aimed at improving hemostasis. SETTINGS AND DESIGN Data was obtained from an international peer-reviewed registry haemostasis.com. This registry...
متن کاملOff-label use of recombinant factor VIIa in pediatric patients.
OBJECTIVE To examine off-label recombinant factor VIIa (rFVIIa) use in pediatric patients including clinical indications, dose, adverse events, and outcomes. METHODS All pediatric patients entered into the Haemostasis Registry from 75 participating hospitals were analyzed. RESULTS Three hundred and eighty-eight pediatric patients received off-label rFVIIa from 2003 to 2009. Median age was 1...
متن کاملUse of recombinant factor VIIa for major haemorrhage.
EDITOR: Haemorrhage associated with trauma and surgery remains a significant cause of death. The development of coagulopathic bleeding is often difficult to manage. Recombinant-activated factor VII (rFVIIa, NovoSeven®; Novo Nordisk, Bagsvaerd, Denmark), which is structurally similar to the naturally occurring activated coagulation factor VII, is licensed for use in patients with haemophilia A o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Global Journal on Quality and Safety in Healthcare
سال: 2020
ISSN: 2589-9449,2666-2353
DOI: 10.36401/jqsh-19-41